The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer
Open accessAbstract
BACKGROUND: Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1). METHODS: Patients with advanced thyroid cancer were enrolled in the nonrandomized, phase Ib KEYNOTE-028 trial conducted to evaluate safety and antitumor activity of the anti-programmed death 1 (PD-1) antibody pembrolizumab in advanced solid tumors. Key eligibility criteria were advanced papillary or follicular thyroid cancer, failure of standard therapy, and PD-L1 expression in tumor or stroma cells (assessed by immunohistochemistry). Pembrolizumab 10 mg/kg was administered every 2 weeks up to 24 months or until confirmed progression or intolerable toxicity. The primary endpoint was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: Twenty-two patients were enrolled: median age was 61 years; 59% were women; and 68% had papillary carcinoma. Median follow-up was 31 months (range, 7-34 months). Treatment-related adverse events were observed in 18 (82%) patients; those occurring in ≥15% of patients were diarrhea (n = 7) and fatigue (n = 4). One grade ≥ 3 treatment-related adverse event occurred (colitis, grade 3); no treatment-related discontinuations or deaths occurred. Two patients had confirmed partial response, for an ORR of 9% (95% confidence interval [CI], 1-29%); response duration was 8 and 20 months. Median progression-free survival was 7 months (95% CI, 2-14 months); median overall survival was not reached (95% CI, 22 months to not reached). CONCLUSIONS: Results of this phase Ib proof-of-concept study suggest that pembrolizumab has a manageable safety profile and demonstrate evidence of antitumor activity in advanced differentiated thyroid cancer in a minority of patients treated. Further analyses are necessary to confirm these findings. TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT02054806 . Registered 4 February 2014.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Seiwert, T. Y., Burtness, B., Mehra, R., Weiss, J., Berger, R., Eder, J. P., Heath, K., McClanahan, T., Lunceford, J., Gause, C., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30066-3 · Cited by 1,745 · cited 1×
“The safety profile was generally consistent with that observed previously for pembrolizumab [19, 20].”
ResultSelf-citation
Cited by
Ringel, M. D., Sosa, J. A., Baloch, Z., Bischoff, L., Bloom, G., Brent, G. A., Brock, P. L., Chou, R., Flavell, R. R., Goldner, W., et al. (2025) · Thyroid® · doi:10.1177/10507256251363120 · Cited by 710
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Cabanillas, M. E., Ryder, M., & Jimenez, C. (2019) · Endocrine Reviews · doi:10.1210/er.2019-00007 · Cited by 335
New Therapies for Advanced Thyroid Cancer
Laha, D., Nilubol, N., & Boufraqech, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00082 · Cited by 261
Pu, W., Shi, X., Yu, P., Zhang, M., Liu, Z., Tan, L., Han, P., Wang, Y., Ji, D., Gan, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26343-3 · Cited by 261
Dierks, C., Seufert, J., Aumann, K., Ruf, J., Klein, C., Kiefer, S., Rassner, M., Boerries, M., Zielke, A., la Rosee, P., et al. (2021) · Thyroid · doi:10.1089/thy.2020.0322 · Cited by 254
Metadata
- Authors
- Mehnert, J. M., Varga, A., Brose, M. S., Aggarwal, R. R., Lin, C.-C., Prawira, A., de Braud, F., Tamura, K., Doi, T., Piha-Paul, S. A., Gilbert, J., Saraf, S., Thanigaimani, P., Cheng, J. D., & Keam, B.
- Venue
- BMC Cancer
- Published
- 2019-03-04
- Volume
- 19
- Issue
- 1
- Pages
- 196-196
- ISSN
- 1471-2407 (ISSN-L)
- OpenAlex
- W2935709215
- Cited by
- 215
- References
- 2
- FWCI
- 20.48
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. https://app.cochat.ai/papers/10.1186/s12885-019-5380-3
- The paper
- Mehnert, J. M., Varga, A., Brose, M. S., Aggarwal, R. R., Lin, C.-C., Prawira, A., de Braud, F., Tamura, K., Doi, T., Piha-Paul, S. A., Gilbert, J., Saraf, S., Thanigaimani, P., Cheng, J. D., & Keam, B. (2019). Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer. BMC Cancer. https://doi.org/10.1186/s12885-019-5380-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.